Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Safety and Nanotoxicity Aspects of Nanomedicines for Brain-Targeted Drug Delivery
Department of Pharmaceutical Science and Technology, School of Chemical and Pharmaceutical Sciences, University of Chile, Santiago, Chile; Department of Biochemistry, School of Chemical and Pharmaceutical Sciences, University of Chile, Santiago, Chile; Experimental Pharmacology Institute, CONICET, National University of Cordoba, Cordoba, Argentina; Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile.
Luleå University of Technology, Department of Health Sciences. Department of Pharmaceutical Science and Technology, School of Chemical and Pharmaceutical Sciences, University of Chile, Santiago, Chile; Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile; Center of New Drugs for Hypertension (CENDHY), Santiago, Chile. (Pharmaceutical and Biomaterial Research Group)
2021 (English)In: Nanomedicines for Brain Drug Delivery / [ed] Javier O. Morales; Pieter J. Gaillard, Springer, 2021, p. 255-277Chapter in book (Refereed)
Abstract [en]

Nanotechnology for brain drug delivery comprises the promise for future possibilities of successful treatment in several central nervous system pathologies currently deficient of curative treatments, such as neurodegenerative disorders and malignant glioblastoma. Nevertheless, the neurotoxic effects exerted by several types of nanomaterials are the same as those involved in the pathology of neurodegeneration; thus it is important to have a deep knowledge of these mechanisms, so that a proper approach can be taken into consideration. On the other hand, cancer cells usually respond differently to normal cells, being this characteristic a potential advantage for brain cancer therapy. In this chapter we analyze the mechanisms behind neurotoxic effects, from a multidisciplinary perspective, aiming to highlight the disadvantages of nanomaterials for the development of brain-targeted nanocarriers. 

Place, publisher, year, edition, pages
Springer, 2021. p. 255-277
Series
Neuromethods, ISSN 0893-2336, E-ISSN 1940-6045
Keywords [en]
Neurotoxicity, Neurodegeneration, Nanoparticle toxicity, Brain, Autophagy, Oxidative stress
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:ltu:diva-86805DOI: 10.1007/978-1-0716-0838-8_10Scopus ID: 2-s2.0-85096538525OAI: oai:DiVA.org:ltu-86805DiVA, id: diva2:1587204
Note

ISBN för värdpublikation: 978-1-0716-0837-1; 978-1-0716-0838-8;

Forskningsfinansiär: ANID/FONDECYT Regular/1181689; ANID/PIA/ACT192144; ANID/FONDAP/15130011

Available from: 2021-08-24 Created: 2021-08-24 Last updated: 2021-08-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus
By organisation
Department of Health Sciences
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 46 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf